» Articles » PMID: 37466835

Anti-PCSK9 Treatment Attenuates Liver Fibrosis Via Inhibiting Hypoxia-Induced Autophagy in Hepatocytes

Overview
Journal Inflammation
Date 2023 Jul 19
PMID 37466835
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia and its induced autophagy are involved in the initiation and progression of liver fibrosis. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recognized as a potential regulator of autophagy. Our previously reported study found that PCSK9 expression increased in liver fibrosis and that anti-PCSK9 treatment alleviated liver injury. This study aimed to investigate the mechanism of anti-PCSK9 treatment on liver fibrosis by inhibiting hypoxia-induced autophagy. Carbon tetrachloride-induced mouse liver fibrosis and mouse hepatocyte line AML12, cultured under the hypoxic condition, were established to undergo PCSK9 inhibition. The degree of liver fibrosis was shown with histological staining. The reactive oxygen species (ROS) generation was detected by flow cytometry. The expression of PCSK9, hypoxia-inducible factor-1α (HIF-1α), and autophagy-related proteins was examined using Western blot. The autophagic flux was assessed under immunofluorescence and transmission electron microscope. The mouse liver samples were investigated via RNA-sequencing to explore the underlying signaling pathway. The results showed that PCSK9 expression was upregulated with the development of liver fibrosis, which was accompanied by enhanced autophagy. In vitro data verified that PCSK9 increased via hypoxia and inflammation, accompanied by the hypoxia-induced autophagy increased. Then, the validation was acquired of the bidirectional interaction of hypoxia-ROS and PCSK9. The hypoxia reversal attenuated PCSK9 expression and autophagy. Additionally, anti-PCSK9 treatment alleviated liver inflammation and fibrosis, reducing hypoxia and autophagy in vivo. In mechanism, the AMPK/mTOR/ULK1 signaling pathway was identified as a target for anti-PCSK9 therapy. In conclusion, anti-PCSK9 treatment could alleviate liver inflammation and fibrosis by regulating AMPK/mTOR/ULK1 signaling pathway to reduce hypoxia-induced autophagy in hepatocytes.

Citing Articles

Assessment of hypoxia status in a rat chronic liver disease model using IVIM and T1 mapping.

Dong W, Xiao L, Luo Z, Yu H, Wang L, Gao Y Front Med (Lausanne). 2025; 11:1477685.

PMID: 39906347 PMC: 11790595. DOI: 10.3389/fmed.2024.1477685.


The Biology and Clinical Implications of PCSK7.

Sachan V, Susan-Resiga D, Lam K, Seidah N Endocr Rev. 2024; 46(2):281-299.

PMID: 39661471 PMC: 11894536. DOI: 10.1210/endrev/bnae031.


Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study.

Cai G, Liu J, Cai M, Shao L Lipids Health Dis. 2024; 23(1):237.

PMID: 39090671 PMC: 11293199. DOI: 10.1186/s12944-024-02218-6.

References
1.
Peng J, Liu M, Jin J, Cao Y, Guo Y, Wu N . NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. Lipids Health Dis. 2022; 21(1):3. PMC: 8742334. DOI: 10.1186/s12944-021-01610-w. View

2.
Ruscica M, Ferri N, Macchi C, Meroni M, Lanti C, Ricci C . Liver fat accumulation is associated with circulating PCSK9. Ann Med. 2016; 48(5):384-91. DOI: 10.1080/07853890.2016.1188328. View

3.
Dwivedi D, Grin P, Khan M, Prat A, Zhou J, Fox-Robichaud A . Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis. Shock. 2016; 46(6):672-680. DOI: 10.1097/SHK.0000000000000682. View

4.
Bi G, Bian Y, Liang J, Yin J, Li R, Zhao M . Pan-cancer characterization of metabolism-related biomarkers identifies potential therapeutic targets. J Transl Med. 2021; 19(1):219. PMC: 8142489. DOI: 10.1186/s12967-021-02889-0. View

5.
Ding Z, Wang X, Liu S, Shahanawaz J, Theus S, Fan Y . PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy. Cardiovasc Res. 2018; 114(13):1738-1751. DOI: 10.1093/cvr/cvy128. View